MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines, therapies, and digital medicine to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, an Ibogaine derivative called 18-MC and a digital medicine platform that uses Artificial Intelligence (AI)-enabled digital measurement to increase the precision and speed of clinical research and patient monitoring. MindMed is building the toolset for mental healing - from breakthrough medicines and technology to experiential therapy - for patients and therapists that accounts for the entire, complex patient journey.